Positive results for an anti-amyloid agent in patients with early-stage Alzheimer’s disease (AD) is drawing praise, but experts are calling for caution.

Results from the new phase 2 study showed a statistically significant reduction in brain amyloid with a high dose of BAN2401 (Eisai Co. Ltd/Biogen Inc) at 18 months.

In addition, the study showed a dose-dependent, statistically significant, and clinically meaningful slower decline in cognition and function with the highest dose compared to placebo.

This is the first large clinical trial to support the amyloid hypothesis.